Auransa is redefining precision medicine by using AI and genomics to develop treatments that address the unmet needs of significant patient subpopulations.
Nulla adipisicing do ut aliquip elit tempor fugiat. Mollit est exercitation excepteur ea consequat ullamco Lorem ex id. Ipsum nostrud Lorem dolor nisi do est in ex amet eu nostrud. Amet commodo consectetur enim nostrud dolore sint excepteur irure aliqua consectetur. Veniam occaecat et enim eiusmod qui fugiat eiusmod eiusmod laborum exercitation veniam ipsum velit. Ut veniam cupidatat ea tempor ad ad exercitation amet qui. Esse commodo sint deserunt ut elit minim sint. Amet laborum ut adipisicing minim sunt cillum anim in est ipsum aliquip anim in tempor pariatur.
Biology Biochemistry
Advancing Human Health
Lux investment: 2014
Pek Lum
Viwat Visuthikraisee
Auransa
Similar companies
Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2019
Eric Betzig
Robert Tjian
Luke Lavis
Xavier Darzacq
Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis.
Biology Biochemistry
Advancing Human Health
Lux founded: 2015
Richard Axel
Tom Maniatis
Charles Zuker
Nancy Thornberry
Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. The company completed its IPO [NASDAQ: RXRX] in 2021.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2016
IPO: 2021
Chris Gibson, PhD
Blake Borgeson, PhD
Dean Li, PhD
Auris Healthis an ambitious robotics company based in Silicon Valley. Auris was acquired for up to $6.1B by Johnson & Johnson in 2019.
Engineering Electronics
Advancing Human Health
Increasing Productivity Efficiency
Lux investment: 2012
Acquired by JNJ: 2019
Fred Moll
ESM3 is the first generative AI model for biology that simultaneously reasons over the sequence, structure, and function of proteins. This enables scientists to understand and create new proteins, making biology programmable.
Biology Biochemistry
Lux investment: 2023
Alex Rives
Tom Sercu
Sal Candido
Cajal Neuroscienceis a drug discovery company focused on neurodegenerative disease.
Biology Biochemistry
Advancing Human Health
Progressing Science Knowledge
Lux investment: 2020
Ian Peikon, PhD
Charles Zuker, PhD
Huda Zoghbi, MD
Tony Zador, MD, PhD
Rob Hershberg, MD, PhD
Andrew Dervan, MD